» Authors » Stephen S Taylor

Stephen S Taylor

Explore the profile of Stephen S Taylor including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 57
Citations 4673
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Morgan R, Wang X, Barnes B, Spurgeon L, Carrot A, Netto D, et al.
Br J Cancer . 2024 Nov; 131(12):1919-1927. PMID: 39550490
Background: High-grade serous ovarian cancer (HGSOC) can be treated with platinum-based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS). Histopathological response to NACT can be assessed using Böhm's chemotherapy response...
2.
Morgan R, Burghel G, Flaum N, Schlecht H, Clamp A, Hasan J, et al.
Genet Med . 2024 Aug; 26(10):101230. PMID: 39096152
Purpose: The prevalence of germline pathogenic variants (PVs) in homologous recombination repair (HRR) and Lynch syndrome (LS) genes in ovarian cancer (OC) is uncertain. Methods: An observational study reporting the...
3.
Coulson-Gilmer C, Littler S, Barnes B, Brady R, Anagho H, Pillay N, et al.
NAR Cancer . 2024 Jul; 6(3):zcae030. PMID: 39015544
A subset of cancer cells are intrinsically sensitive to inhibitors targeting PARG, the poly(ADP-ribose) glycohydrolase that degrades PAR chains. Sensitivity is accompanied by persistent DNA replication stress, and can be...
4.
Scelfo A, Angrisani A, Grillo M, Barnes B, Muyas F, Sauer C, et al.
Mol Cell . 2024 Feb; 84(6):1003-1020.e10. PMID: 38359824
The high incidence of whole-arm chromosome aneuploidy and translocations in tumors suggests instability of centromeres, unique loci built on repetitive sequences and essential for chromosome separation. The causes behind this...
5.
Nelson L, Barnes B, Tighe A, Littler S, Coulson-Gilmer C, Golder A, et al.
Chromosome Res . 2023 Aug; 31(3):21. PMID: 37592171
Chromosome instability (CIN) is a cancer hallmark that drives tumour heterogeneity, phenotypic adaptation, drug resistance and poor prognosis. High-grade serous ovarian cancer (HGSOC), one of the most chromosomally unstable tumour...
6.
Morgan R, Clamp A, Barnes B, Timms K, Schlecht H, Yarram-Smith L, et al.
Int J Gynecol Cancer . 2023 Apr; 33(8):1253-1259. PMID: 37072323
Objective: Olaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer with a deficiency in homologous recombination. We report data from the first...
7.
Golder A, Nelson L, Tighe A, Barnes B, Coulson-Gilmer C, Morgan R, et al.
NAR Cancer . 2022 Nov; 4(4):zcac036. PMID: 36381271
High-grade serous ovarian cancer (HGSOC) is an aggressive disease that typically develops drug resistance, thus novel biomarker-driven strategies are required. Targeted therapy focuses on synthetic lethality-pioneered by PARP inhibition of...
8.
Amalina I, Bennett A, Whalley H, Perera D, McGrail J, Tighe A, et al.
R Soc Open Sci . 2021 Dec; 8(12):210854. PMID: 34925867
Bub1 is a serine/threonine kinase proposed to function centrally in mitotic chromosome alignment and the spindle assembly checkpoint (SAC); however, its role remains controversial. Although it is well documented that...
9.
Coulson-Gilmer C, Morgan R, Nelson L, Barnes B, Tighe A, Wardenaar R, et al.
J Exp Clin Cancer Res . 2021 Oct; 40(1):323. PMID: 34656146
Background: Patients with ovarian cancer often present at advanced stage and, following initial treatment success, develop recurrent drug-resistant disease. PARP inhibitors (PARPi) are yielding unprecedented survival benefits for women with...
10.
Bronder D, Tighe A, Wangsa D, Zong D, Meyer T, Wardenaar R, et al.
Dis Model Mech . 2021 Sep; 14(11). PMID: 34569598
High-grade serous ovarian cancer (HGSOC) originates in the fallopian tube epithelium and is characterized by ubiquitous TP53 mutation and extensive chromosomal instability (CIN). However, direct causes of CIN, such as...